¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"systemic inflammatory response syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
¿µ¹® nephrotic syndrome ÇÑ±Û ÄáÆÏÁõÈıº
¼³¸í   
  ÄáÆÏÀÇ Å丮À̻󿡠ÀÇÇÑ ´Ü¹éÁú¼Õ½ÇÀÌ ÁÖ¿øÀÎÀΠº´ÀÌ´Ù. ±× Á¤ÀǴ ¼ºÀÎÀÇ ¿ä´Ü¹é·®(¼Òº¯¿¡ ¼¯¿© ³ª¿À´Â ´Ü¹éÁúÀÇ ¾ç. ´ë°³ Á¤»óÀο¡¼­´Â ³ª¿ÀÁö ¾Ê°Å³ª, È¤Àº ¾ÆÁÖ ¼Ò·®ÀÌ ³ª¿Ã »ÓÀÓ)ÀÌ ÇÏ·ç 3.5mgÀÌ»ó, ¶ÇÇÑ ¼Ò¾Æ¿¡¼­´Â Ç÷Áß ¾ËºÎ¹Î³óµµ°¡ 2.5mgÀÌÇÏ, ÇÏ·íµ¿¾È ¼Òº¯À¸·Î ³ª¿À´Â ¿ä´Ü¹é·®À» ½Ã°£´ç °è»êÇßÀ» ¶§ ½Ã°£´ç 40mgÀÌ»óÀΠ°æ¿ìÀÌ´Ù. µû¶ó¼­ ÄáÆÏÁõÈıºÀ̶õ À§ÀÇ Á¤ÀÇ¿¡ ÇÕ´çÇϱ⸸ Çϸ頸ðµÎ ÇØ´çµÇ¹Ç·Î, ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇÑ ÄáÆÏÀÌ»óÀ¸·Î¼­ ´Ü¹éÁúÀÇ Áö³ªÄ£ ¹èÃâÀ» ³ªÅ¸³»´Â Áúº´ÀÇ ÁýÇÕü¸¦ ¶æÇÑ´Ù. ´ë°³ Áõ»óÀº Áö³ªÄ£ Ç÷ÁߴܹéÁúÀÇ °¨¼Ò·Î ÀÎÇÑ ºÎÁ¾, ±×¸®°í ÀÌÂ÷ÀûÀΠÁõ»óÀ¸·Î ¹ß»ýÇÑ °íÁöÁúÇ÷Áõ, °¨¿°°¨¼ö¼ºÀÇ Áõ°¡, °íÇ÷¾Ð µîÀÌ´Ù. Ä¡·á¿Í ¿¹ÈĴ ÄáÆÏÁõÈıºÀ» ³ªÅ¸³»´Â °¢ ¿øÀο¡ µû¶ó ´Ù¸£³ª, ´ë°³ ¼Ò¾Æ¿¡ ¹ß»ýÇÑ °æ¿ì ½ºÅ×·ÎÀ̵åÁ¦Àç¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù.
¿µ¹® Cushing's syndrome ÇÑ±Û Äí½ÌÁõÈıº
¼³¸í   
  Äí½ÌÁõÈıºÀ̶õ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ¸¸¼ºÀûÀ¸·Î °úÀ׺кñ¿¡ ÀÇÇØ¼­ ÀϾ´Â º´À» ¸»ÇÑ´Ù.
  
  ¿øÀÎÀ¸·Î ¨ç ³úÇϼöü¿¡¼­ ACTH°¡ °úÀ× ºÐºñµÇ´Â °æ¿ì: ³úÇϼöü¿¡¼­ ACTH°¡ ³Ê¹«³ª ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì¿¡ ºÎ½Å°ÑÁúÀ» ÀÚ±ØÇؼ­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨è ³úÇϼöü ÀÌ¿ÜÀÇ ºÎºÐ¿¡¼­ ACTH°¡ ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì: Æó¾Ï, ³­¼Ò¾Ï µîÀÇ Á¾¾ç¿¡¼­ ACTH¸¦ »ý»êÇϴ °æ¿ì°¡ ÀÖ´Ù. ÀÌ °æ¿ì¿¡µµ ¿ª½Ã ºÎ½ÅÇÇÁúÀÌ ÀÚ±ØÀÌ µÇ¾î¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨é ACTHÀÇ ÀÚ±ØÀÌ ¾øÀÌ ºÎ½Å¿¡¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ³ª¿À´Â °æ¿ì. ACTHÀڱؿ¡ °ü°è¾øÀÌ ºÎ½ÅÇÇÁúÀÇ °úÀ×¼ºÀå, Á¾¾ç¿¡ ÀÇÇØ¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÇ´Â °æ¿ì. ¨ê ¿ÜÀμº, ÀÇÀμº: Ä¡·á¸¦ À§Çؼ­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵带 Àå±â Åõ¿©ÇÒ °æ¿ì¿¡ »ý±â´Â Äí½ÌÁõÈıº
  
  Äí½ÌÁõÈıº¿¡¼­ Æ¯È÷ ¨ç¹ø¿¡ ÇØ´çÇϴ °ÍÀ» Äí½Ìº´¶ó°í ÇÑ´Ù.
  
  Áõ»óÀº ¶×¶×ÇÏ°í ¾ó±¼ÀÌ ´Þµ¢ÀÌó·³ µÕ±Û°í »ìÀÌ ÂÈÁö¸¸ ÆÈ, ´Ù¸®´Â °¡´Ã°í ´ë½Å¿¡ ¸ö¿¡ ¸¹Àº »ìÀÌ ºÙ¾îÀÖ´Ù. ¸ñµÚ¿¡ ¸¹Àº »ìÀÌ À־ ±×°ÍÀÌ µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ ÇÑ´Ù. À̰ÍÀº ¿ø·¡ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 Áö¹æÀ» ºÐÇØÇϴ ¿ªÇÒÀ» ÇÏÁö¸¸ º´ÀûÀ¸·Î ¸¹ÀÌ ³ª¿Ã °æ¿ì¿¡´Â Áö¹æÀÇ ºÐÆ÷¸¦ º¯È­½Ã۴ ¿ªÇÒÀ» Çϱ⠶§¹®ÀÌ´Ù. Áï ÆÈ, ´Ù¸® µîÀÇ ¿Â¸ö¿¡ ÆÛÁ®Àִ Áö¹æÀ» ¸öÅëÂÊÀ¸·Î ¸ðµÎ À̵¿½ÃŲ´Ù. ÀÜÅÐÀÌ ¿Â¸ö¿¡ °ÉÃļ­ ¸¹ÀÌ ³ªÀÖ°í ¿©µå¸§ÀÌ ¸¹°í ¹è¿¡ ÀÚÁÖ»ö ¼±Á¶°¡ Àִ °æ¿ì°¡ ¸¹´Ù. ±×¸®°í ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ´Ü¹éÁúÀ» ºÐÇØÇØ¼­ ´ç·ù¸¦ ¸¸µå´Â ¿ªÇÒÀ» ÇÏ¿© ±ÙÀ°À̳ª »À´ëÀÇ ½ÉÇÑ ¼Ò½ÇÀÌ ÀÖ´Ù. ±×·¡¼­ ±ÙÀ°ÀÌ °ÅÀÇ ¾ø¾îÁö°í »À´Â ¾ÆÁÖ ºÎ·¯Áö±â ½±°Ô µÈ´Ù. ´ë°³ °íÇ÷¾ÐÀΠ°æ¿ì°¡ ¸¹°í ½É¸®ÀûÀ¸·Î ¿ì¿ïÁõÀ̳ª °ú¹Î¼º µîÀÌ ÀÖÀ» ¼öµµ ÀÖ°í ½ÉÇÑ °æ¿ì¿¡´Â Á¤½Åº´Áõ¼¼¸¦ º¸À̱⵵ ÇÑ´Ù.
¿µ¹® Klinefelter syndrome ÇÑ±Û Å¬¶óÀÎÆçÅÍÁõÈıº
¼³¸í   
  1942³â H.F. Å¬¶óÀÎÆçÅͰ¡ ±âÀçÇÑ ¼º¿°»öüÀÌ»óÁõÈıº. Á¤»óÀÎÀÇ ¼º¿°»öüÇüÀº ³²¼º XY, ¿©¼º XX¸¦ ³ªÅ¸³»Áö¸¸, ÀÌ ÁõÈıº¿¡¼­´Â ¼º¿°»öüÇüÀÌ XXY. XXYY, XXXXY µîÀÇ ¿©·¯ °¡Áö ÀÌ»óÇÑ ÇüŸ¦ ³ªÅ¸³½´Ù. ¿Ü¼º±â-ü°Ý-¼ºÂ¡ µîÀǠƯ¡ÀûÀΠÁõ¼¼·Î º¼ ¶§¿¡ ¿ÏÀüÇÑ ³²¼ºÀÌ °áÈ¥ÇÏ¿© ¼º»ýȰ±îÁö ÇÏ¿´À¸³ª, ÀÚ½ÄÀÌ ¾øÀÚ ºÎºÎ°¡ ÇÔ²² º´¿øÀ» Ã£¾Æ°¡¼­ ¿°»öü¸¦ °Ë»çÇØ º¸°í ³²ÀÚ¿¡°Ô ÀÌ ÁõÈıºÀÌ ÀÖÀ½À» ¾Ë°Ô µÇ´Â °æ¿ì°¡ ¸¹´Ù. ÀÌ ¹Û¿¡ ¼ºÀÎÀÌ µÇ¾î ³ªÅ¸³ª´Â ÁÖ¿ä Áõ¼¼¸¦ µé¸é, ÀÛÀº°íȯ, ¿©¼ºÇü À¯¹æÁõ, ¹«Á¤ÀÚÁõ, ºÒÀÓ, ¿äÁß °í³ªµµÆ®·ÎÇÉÀÇ »ó½Â, Áö´É ÀúÇÏ µîÀÌ´Ù. Ä¡·á´Â 2Â÷ ¼ºÂ¡ÀÇ ÃËÁøÀ» À§ÇÏ¿© È£¸£¸ó¿ä¹ý¿¡ ÀÇÇÑ ³²¼ºÈ­¸¦ ½ÃµµÇÑ´Ù.
¿µ¹® fetal alcohol syndrome ÇÑ±Û Å¾ƾËÄÚ¿ÃÁõÈıº
¼³¸í   
  ÀӽűⰣ Áß ¸¸¼ºÀûÀ¸·Î ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ¿©ÀÚ¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô ³ªÅ¸³ª´Â ÇüŹ߻ýÀÇ ÀÌ»óÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î¼­ À§ÅλÀ¹ßÀ°ºÎÀü, ¾Õ¸Ó¸®¿Í ¾Æ·¡ÅÎÀÇ µ¹Ãâ, ÂªÀº°Ë¿­, ÀÛÀº¾È±¸Áõ, ´«±¸¼®ÁÖ¸§, ½ÉÇÑ ¼ºÀåÁö¿¬, Á¤½ÅÁöü µîÀ» ³ªÅ¸³½´Ù.
¿µ¹® Horner syndrome ÇÑ±Û È£¸£³ÊÁõÈıº
¼³¸í   
  ±³°¨½Å°æ°æ·ÎÀÇ Àå¾Ö·Î »ý±â´Â º´ÀÌ´Ù. ±³°¨½Å°æÀº ÀÚÀ²½Å°æÀÇ Çϳª·Î ¿Â¸ö¿¡ ºÐÆ÷¸¦ ÇÑ´Ù. Æ¯È÷ ¾ó±¼ÂÊ¿¡´Â ´«²¨ÇÃÀ» ¿Ã¸®´Â ±ÙÀ°°ú ¶¡»ù¿¡ ºÐÆ÷Çϰí ÀÖ´Ù. À̿͠°°Àº ±³°¨½Å°æÀÇ ÀÛ¿ëÀ¸·Î ´«²¨Ç®À» Á¤»óÀûÀ¸·Î ¿Ã¸®°í ¾ó±¼¿¡ ¶¡ÀÌ ³ª¿À°Ô µÈ´Ù. ±× ¿Ü¿¡µµ ´«ÀÇ ºûÀÇ ¾çÀ» Á¶ÀýÇϴ ȫ並 ¼öÃà½Ã۴ ±ÙÀ°¿¡ ºÐÆ÷ÇØ¼­ ±× ÀÛ¿ëÀ¸·Î ´«ÀǠȫä°¡ ¼öÃàÇÏ¿© µ¿°øÀÌ Ä¿Áö°Ô µÈ´Ù. ±³°¨½Å°æÀº ±× ±â¿øÀÌ ´ë³ú¼Ó¿¡ Á¸ÀçÇϴ ½Ã»óÇϺζó´Â °÷À̰í À̰÷¿¡¼­ ½ÃÀÛÇÑ ±³°¨½Å°æÀº Ã´¼ö¸¦ Å¸°í ³»·Á¿Í¼­ ¸ñºÎÀ§¿¡¼­ Ã´¼ö¸¦ ºüÁ®³ª¿Í¼­ ±³°¨½Å°æÀ» Áٱ⸦ Çü¼ºÇÏ¿© ´Ù½Ã ³ú·Î °¡´Â Ç÷°üÀ» µû¶ó¼­ ¾ó±¼ÂÊÀ¸·Î °¡°ÔµÈ´Ù. ¸¸¾à ÀÌ ±³°¨½Å°æÀÇ ÁÖÇàºÎÀ§¿¡ º´º¯ÀÌ »ý±â¸é ±×ÂÊÀÇ ¾ó±¼¿¡ ±³°¨½Å°æÀÌ Â÷´ÜµÇ¹Ç·Î º´ÅÍÂÊÀÇ ´«ÀÇ ´«²¨Ç®ÃÄÁü, Ãൿ ±×¸®°í º´º¯Ãø ¾ó±¼ºÎÀÇ ¶¡ÀÌ ³ªÁö ¾Ê´Â °Í µîÀÇ Áõ»óÀ» ³ªÅ¸³ª°Ô µÈ´Ù. ÀÌ·± Çö»óÀ» È£¸£³ÊÁõÈıºÀ̶ó°í ÇÑ´Ù. À̰ÍÀº ¿©·¯ °¡Áö º´¿¡¼­ ³ªÅ¸³¯ ¼ö°¡ Àִµ¥ ³ú³ª Ã´¼öÀÇ ÁúȯÁß¿¡¼­ ÀÌ ±³°¨½Å°æ·Î¸¦ ¾Ð¹ÚÇϰųª Ä§¹üÇϴ º´¿¡¼­ »ý±æ ¼öµµ ÀÖÀ¸¸ç, ¶Ç´Â Æó¾ÏÀ̠ô¼ö¿¡¼­ ºüÁ®³ª¿Í ¸ñºÎºÐ¿¡¼­ ÀÌ·é ±³°¨½Å°æÀÇ Áٱ⸦ ´©¸¦ °æ¿ì¿¡µµ »ý±æ ¼öµµ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£, Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£
  • late asthmatic response
    ¸¸±âõ½Ä¹ÝÀÀ, Èıâõ½Ä¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
  • middle latency response
    Áß°£Àẹ¹ÝÀÀ
  • myotatic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ, Çö󼼺¸¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ìµå·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response
    ¹ÝÀÀ
  • response bias
    ¹ÝÀÀÄ¡¿ìħ
  • response curve
    ¹ÝÀÀ°î¼±
  • response decline
    ¹ÝÀÀ°¨¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • nephritic syndrome
    ÄáÆÏ¿°ÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº, ½ÅÁõÈıº
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • overuse syndrome
    °úµµ»ç¿ëÁõÈıº
  • paraneoplastic syndrome
    ½Å»ý¹°µþ¸²ÁõÈıº
  • Parkinson's syndrome
    ÆÄŲ½¼ÁõÈıº
  • polycystic ovarian syndrome
    ´Ù³¶³­¼ÒÁõÈıº, ¹µÁָӴϳ­¼ÒÁõÈıº
  • Raynaud syndrome
    ·¹À̳ëÁõÈıº
  • respiratory distress syndrome
    È£Èí°ï¶õÁõÈıº
  • respiratory disturbance syndrome
    È£ÈíÀå¾ÖÁõÈıº
  • retraction syndrome
    ¾È±¸ÈÄÅðÁõÈıº
  • severe acute respiratory syndrome
    ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
  • Sheehan's syndrome
    ½¬ÇÑÁõÈıº
  • short bowel syndrome
    ªÀºÃ¢ÀÚÁõÈıº
  • sick building syndrome
    ºôµùÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • response curve
    ¹ÝÀÀ°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • delayed response
    Áö¿¬¹ÝÀÀ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • emotional response
    °¨Á¤¹ÝÀÀ
  • evoked response
    À¯¹ß¹ÝÀÀ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦
  • inert response
    ºÒȰ¼º¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Browns syndrome->superior oblique tendon sheath syndrome
    ºê¶ó¿îÁõÈıº
  • Cowdens syndrome = multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
  • ICE syndrome=iridocorneal endothelial syndrome
    ȫä°¢¸·³»ÇÇÁõÈıº
  • Lowes syndrome->oculocerebrorenal syndrome
    ·Î¿ìÁõÈıº
  • PIE syndrome => pulmonary infiltration with eosinophilia syndrome
    È£»ê±¸Áõ°¡¼º ÆóħÀ± ÁõÈıº
  • Q-T prolongation syndrome ; long Q-T syndrome
    Q-T°£°Ý ¿¬ÀåÁõÈıº.
  • Raeders syndrome=>painful Horners syndrome
    ·¹ÀÌ´õÁõÈıº
  • Steiners syndrome [=curtius syndrome, facial hemi
    ¾È¸é¹Ý(ÂÊ)ºñ´ëÁõ
  • UGH syndrome->uveitis-glaucoma-hemorrhage syndrome
    À¯Áö¿¡ÀÌÃëÁõÈıº
  • A-V syndrome
    A-VÁõÈıº
  • Acquiered immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª °áÇÌÁõÈıº
  • Adams Stokes syndrome
    ¾Ö´ý½º-½ºÅäÅ©½ºÁõÈıº.
  • Albrights syndrome
    ¾Ëºê¶óÀÌÆ® ÁõÈıº(~ ñøý¦ÏØ)
  • Alezzandrinis syndrome
    ¾Ë·¹Àܵ帮´ÏÁõÈıº
  • Alports syndrome
    ¾ËÆ÷Æ® ÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • systemic circulation
    ü¼øÈ¯(ô÷âàü»).
  • systemic death
    Àü½Å»ç(îïãóÞÝ)
  • systemic herpes zoster
    Àü½Å ´ë»ó Æ÷Áø
  • systemic hypotension
    Àü½Å¼º ÀúÇ÷¾Ð(Áõ)(îï ãóàõî¸úìäâñø).
  • systemic hypotension
    Àü½Å¼º ÀúÇ÷¾Ð(Áõ)(îï ãóàõî¸úìäâñø)
  • systemic infection
    Àü½Å¼º °¨¿°(Áõ) (¡­Êïæøñø).
  • systemic lesion
    Àü½Å¼º º´º¯(¡­Ü»Ü¨)
  • systemic lupus erythematosus
    Àü½Å¼ºÈ«¹Ý¼º·çÇÁ½º
  • systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º(îïãóàõûõÚèàõ)·çǪ½º
  • systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º(îïãóàõûõÚèàõ)·çǪ½º.
  • systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º(îïãóàõûõÚèàõ)·çǪ½º
  • systemic mastocytosis
    Àü½Å¼º ºñ¸¸¼¼Æ÷Áõ(¡­ÝþØ»á¬øàñø).
  • systemic mastocytosis
    Àü½Å¼º ºñ¸¸¼¼Æ÷Áõ(¡­ÝþØ»á¬øàñø)
  • systemic mycosis
    Àü½Å(¼º) Áø±ÕÁõ
  • systemic nodular panniculitis
    Àü½Å(¼º) °áÀý¼º Áö¹æÃþ¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PPS Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc...
SBS shaken baby syndrome; short bowel syndrome; sick building syndrome; sinobronchial syndrome; small bo...
WS Waardenburg syndrome; ward secretary; Warkany syndrome; Warthin-Starry [stain]; water soluble; water...
CER capital expenditure review; ceramide; conditioned emotional response; control electrical rhythm; cor...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MIP-1 alpha Macrophage Inflammatory Protein 1 alpha
MIP-2 Macrophage inflammatory protein 2
MIP-1beta Macrophage inflammatory protein-1beta
NSAID Non Steroid Anti-Inflammatory Drugs
NSAID Non Steroidal Anti-Inflammatory Drug
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • emotional defense response
    Á¤¼­Àû ¹æ¾î ¹ÝÀÀ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • evoked response
    À¯¹ß ¹ÝÀÀ
  • humoral immunologic response
    ü¾×¼º ¸é¿ª ¹ÝÀÀ
  • immediate response
    Ãʱ⠹ÝÀÀ
    ¾Ë·¹¸£±â ¹ÝÀÀ°ú °°ÀÌ À¯¹ßÀÎÀÚ¿¡ Á¢ÇÑ ÈÄ, ¸î ÃÊ-¸î ºÐ À̳»¿¡ ÃâÇöÇÏ´Â ¹ÝÀÀ.
  • immune response
    ¸é¿ª ¹ÝÀÀ
  • immunologic response
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø¿¡ ³ëÃâµÊÀ¸·Î½á °³Ã¼ÀÇ ¹ÝÀÀ¼ºÀÌ Æ¯ÀÌÀûÀ¸·Î º¯È­ÇÑ »óÅÂ.
  • learned response
    ÇнÀ ¹ÝÀÀ
    ÇнÀÀ» ½ÃŰ´Â ÀÚ°¡ ÀǵµÇÑ ´ë·Î Çൿ. ¿¹¸¦ µé¸é Á¾ÀÌ ¿ï·Áµµ °³°¡ ħÀ» È긮´Â °ÍÀÌ ÀÖ´Ù.
  • localized protective response
    ±¹¼ÒÀû º¸È£ ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû ±â¾ï ¹ÝÀÀ
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • placebo response
    Çö󼼺¸ ¹ÝÀÀ, °¡¾à ¹ÝÀÀ
  • psychophysiologic response
    ½É¸® »ý¸®Àû ¹ÝÀÀ
  • response
    ¹ÝÀÀ, ÀÀ´ä
    Àڱؿ¡ ÀÇÇÏ¿© ÀϾ´Â ÀÛ¿ëÀ̳ª ¿òÁ÷ÀÓ.
  • response to illness
    Áúº´¿¡ ´ëÇÑ ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
biological response modifiers Substances that stimulate the body's response to infection and disease. The body naturally produces small amounts of these substances. Scientists can produce some of them in the laboratory in large amounts and use them in cancer treatment. Also called BRMs.
(12 Dec 1998)
biphasic response Two separate and distinct responses that are separated in time, immediate reaction to an antigenic challenge followed by a recurrence of symptoms after an interval of quiescence.
(05 Mar 2000)
booster response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
brainstem evoked response audiometry An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli.
(05 Mar 2000)
galvanic skin response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
recruiting response <neurology> The gradual increase to a maximum in a reflex when a stimulus of unaltered intensity is prolonged.
(12 Dec 1998)
partial response <oncology> A decrease of at least 50 percent in the sum of the measurements of all evaluable target lesions or tumours seen in a study.
(16 Dec 1997)
relaxation response An integrated hypothalamic reaction resulting in decreased sympathetic nervous system activity which, physiologically and psychologically, is almost a mirror image of the body's response's to Cannon's emergency theory (flight or fight response); can be self-induced through the use of techniques associated with transcendental meditation, yoga, and biofeedback.
See: emergency theory.
(05 Mar 2000)
response An action or movement due to the application of a stimulus.
Origin: L. Respondere = to answer, reply
(18 Nov 1997)
response generalisation <biology> The principle that after an organism learns to respond in a particular manner to a stimulus, that stimulus is effective in eliciting similar responses.
(12 Dec 1998)
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
complete response <oncology> The disappearance of all clinical evidence of disease. Unfortunately, this does not necessarily mean cure, as microscopic metastases may remain undetected, are likely to regrow and become resistant to treatment.
May also be used in relation to a pathological specimen, where no residual abnormality can be detected in the specimen, in which cas it is referred to as a pathological complete reponse.
Acronym: CR
(16 Mar 1998)
concentration-response curve <pharmacology> This is a graph produced to show the relation between the exposure concentration of a drug (or other chemical) and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(05 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á